TGFβ induces proHB-EGF shedding and EGFR transactivation through ADAM activation in gastric cancer cells

Biochemical and Biophysical Research Communications

Volumn 402, Issue 3, 2010, Pages 449-454

  Ebi, Masahide ^a   Kataoka, Hiromi ^a   Shimura, Takaya ^a   Kubota, Eiji ^a   Hirata, Yoshikazu ^a   Mizushima, Takashi ^a   Mizoshita, Tsutomu ^a   Tanaka, Mamoru ^a   Mabuchi, Motoshi ^a   Tsukamoto, Hironobu ^a   Tanida, Satoshi ^a   Kamiya, Takeshi ^a   Higashiyama, Shigeki ^b   Joh, Takashi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

A disintegrin and metalloproteinase (ADAM); Epidermal growth factor receptor (EGFR); Gastric cancer; Heparin binding EGF like growth factor (HB EGF); TGF

Indexed keywords

ADAM PROTEIN; CHOLECYSTOKININ OCTAPEPTIDE; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ARTICLE; CANCER CELL; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH CANCER; TRANSACTIVATION;

ADAM PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA;

EID: 78549279073     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.09.130     Document Type: Article

References (45)

1. Roberts A.B., Anzano M.A., Wakefield L.M., Roche N.S., Stern D.F., Sporn M.B. Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc. Natl. Acad. Sci. USA 1985, 82:119-123.
2. Massague J. TGF-beta signal transduction. Annu. Rev. Biochem. 1998, 67:753-791.
3. Dumont N., Arteaga C.L. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell 2003, 3:531-536.
4. Derynck R., Akhurst R.J., Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 2001, 29:117-129.
5. Miyazono K., Suzuki H., Imamura T. Regulation of TGF-beta signaling and its roles in progression of tumors. Cancer Sci. 2003, 94:230-234.
6. Downing J.R. TGF-beta signaling, tumor suppression, and acute lymphoblastic leukemia. N. Engl. J. Med. 2004, 351:528-530.
7. Prenzel N., Zwick E., Daub H., Leserer M., Abraham R., Wallasch C., Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999, 402:884-888.
8. Asakura M., Kitakaze M., Takashima S., Liao Y., Ishikura F., Yoshinaka T., Ohmoto H., Node K., Yoshino K., Ishiguro H., Asanuma H., Sanada S., Matsumura Y., Takeda H., Beppu S., Tada M., Hori M., Higashiyama S. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat. Med. 2002, 8:35-40.
9. Yamauchi T., Ueki K., Tobe K., Tamemoto H., Sekine N., Wada M., Honjo M., Takahashi M., Takahashi T., Hirai H., Tushima T., Akanuma Y., Fujita T., Komuro I., Yazaki Y., Kadowaki T. Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone. Nature 1997, 390:91-96.
10. Higashiyama S., Abraham J.A., Miller J., Fiddes J.C., Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991, 251:936-939.
11. Voldborg B.R., Damstrup L., Spang-Thomsen M., Poulsen H.S. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann. Oncol. 1997, 8:1197-1206.
12. Andl C.D., Mizushima T., Nakagawa H., Oyama K., Harada H., Chruma K., Herlyn M., Rustgi A.K. Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J. Biol. Chem. 2003, 278:1824-1830.
13. Tanida S., Joh T., Itoh K., Kataoka H., Sasaki M., Ohara H., Nakazawa T., Nomura T., Kinugasa Y., Ohmoto H., Ishiguro H., Yoshino K., Higashiyama S., Itoh M. The mechanism of cleavage of EGFR ligands induced by inflammatory cytokines in gastric cancer cells. Gastroenterology 2004, 127:559-569.
14. Joh T., Kataoka H., Tanida S., Watanabe K., Ohshima T., Sasaki M., Nakao H., Ohhara H., Higashiyama S., Itoh M. Helicobacter pylori-stimulated interleukin-8 (IL-8) promotes cell proliferation through transactivation of epidermal growth factor receptor (EGFR) by disintegrin and metalloproteinase (ADAM) activation. Dig. Dis. Sci. 2005, 50:2081-2089.
15. Fischer O.M., Hart S., Gschwind A., Prenzel N., Ullrich A. Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor. Mol. Cell. Biol. 2004, 24:5172-5183.
16. Schafer B., Marg B., Gschwind A., Ullrich A. Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival. J. Biol. Chem. 2004, 279:47929-47938.
17. Nanba D., Mammoto A., Hashimoto K., Higashiyama S. Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. J. Cell Biol. 2003, 163:489-502.
18. Higashiyama S., Nanba D. ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk. Biochim. Biophys. Acta 2005, 1751:110-117.
19. Higashiyama S., Iwabuki H., Morimoto C., Hieda M., Inoue H., Matsushita N. Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. Cancer Sci. 2008, 99:214-220.
20. Shimura T., Kataoka H., Ogasawara N., Kubota E., Sasaki M., Tanida S., Joh T. Suppression of proHB-EGF carboxy-terminal fragment nuclear translocation: a new molecular target therapy for gastric cancer. Clin. Cancer Res. 2008, 14:3956-3965.
21. Kataoka H. EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments. J. Dermatol. Sci. 2009, 56:148-153.
22. Hirata Y., Ogasawara N., Sasaki M., Mizushima T., Shimura T., Mizoshita T., Mori Y., Kubota E., Wada T., Tanida S., Kataoka H., Kamiya T., Higashiyama S., Joh T. BCL6 degradation caused by the interaction with the C-terminus of pro-HB-EGF induces cyclin D2 expression in gastric cancers. Br. J. Cancer 2009, 100:1320-1329.
23. Lee E., Yi J.Y., Chung E., Son Y. Transforming growth factorbeta(1) transactivates EGFR via an H(2)O(2)-dependent mechanism in squamous carcinoma cell line. Cancer Lett. 2010, 298:107-118.
24. Murillo M.M., del Castillo G., Sanchez A., Fernandez M., Fabregat I. Involvement of EGF receptor and c-Src in the survival signals induced by TGF-beta1 in hepatocytes. Oncogene 2005, 24:4580-4587.
25. Uchiyama-Tanaka Y., Matsubara H., Mori Y., Kosaki A., Kishimoto N., Amano K., Higashiyama S., Iwasaka T. Involvement of HB-EGF and EGF receptor transactivation in TGF-beta-mediated fibronectin expression in mesangial cells. Kidney Int. 2002, 62:799-808.
26. Murillo M.M., Carmona-Cuenca I., Del Castillo G., Ortiz C., Roncero C., Sanchez A., Fernandez M., Fabregat I. Activation of NADPH oxidase by transforming growth factor-beta in hepatocytes mediates up-regulation of epidermal growth factor receptor ligands through a nuclear factor-kappaB-dependent mechanism. Biochem. J. 2007, 405:251-259.
27. Wang S.E., Xiang B., Guix M., Olivares M.G., Parker J., Chung C.H., Pandiella A., Arteaga C.L. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol. Cell Biol. 2008, 28:5605-5620.
28. Tokumaru S., Higashiyama S., Endo T., Nakagawa T., Miyagawa J.I., Yamamori K., Hanakawa Y., Ohmoto H., Yoshino K., Shirakata Y., Matsuzawa Y., Hashimoto K., Taniguchi N. Ectodomain shedding of epidermal growth factor receptor ligands is required for keratinocyte migration in cutaneous wound healing. J. Cell Biol. 2000, 151:209-220.
29. Mochizuki S., Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007, 98:621-628.
30. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat. Rev. Cancer 2008, 8:929-941.
31. Roberts A.B., Wakefield L.M. The two faces of transforming growth factor beta in carcinogenesis. Proc. Natl. Acad. Sci. USA 2003, 100:8621-8623.
32. Bierie B., Moses H.L. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 2006, 6:506-520.
33. Miyazono K. Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2009, 85:314-323.
34. Massague J., Seoane J., Wotton D. Smad transcription factors. Genes Dev. 2005, 19:2783-2810.
35. Wang L.H., Kim S.H., Lee J.H., Choi Y.L., Kim Y.C., Park T.S., Hong Y.C., Wu C.F., Shin Y.K. Inactivation of SMAD4 tumor suppressor gene during gastric carcinoma progression. Clin. Cancer Res. 2007, 13:102-110.
36. Blackford A., Serrano O.K., Wolfgang C.L., Parmigiani G., Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Eshleman J.R., Goggins M., Jaffee E.M., Iacobuzio-Donahue C.A., Maitra A., Cameron J.L., Olino K., Schulick R., Winter J., Herman J.M., Laheru D., Klein A.P., Vogelstein B., Kinzler K.W., Velculescu V.E., Hruban R.H. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin. Cancer Res. 2009, 15:4674-4679.
37. Munoz N.M., Baek J.Y., Grady W.M. TGF-beta has paradoxical and context dependent effects on proliferation and anoikis in human colorectal cancer cell lines. Growth Factors 2008, 26:254-262.
38. Maehara Y., Kakeji Y., Kabashima A., Emi Y., Watanabe A., Akazawa K., Baba H., Kohnoe S., Sugimachi K. Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma. J. Clin. Oncol. 1999, 17:607-614.
39. Komuro A., Yashiro M., Iwata C., Morishita Y., Johansson E., Matsumoto Y., Watanabe A., Aburatani H., Miyoshi H., Kiyono K., Shirai Y.T., Suzuki H.I., Hirakawa K., Kano M.R., Miyazono K. Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling. J. Natl. Cancer Inst. 2009, 101:592-604.
40. Yoshida K., Yokozaki H., Niimoto M., Ito H., Ito M., Tahara E. Expression of TGF-beta and procollagen type I and type III in human gastric carcinomas. Int. J. Cancer 1989, 44:394-398.
41. Kawajiri H., Yashiro M., Shinto O., Nakamura K., Tendo M., Takemura S., Node M., Hamashima Y., Kajimoto T., Sawada T., Ohira M., Hirakawa K. A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma. Clin. Cancer Res. 2008, 14:2850-2860.
42. Nozue M., Nishida M., Todoroki T., Iwasaki Y. Establishment and characterization of a human scirrhus type gastric cancer cell line, GCIY, producing CA19-9. Hum. Cell 1991, 4:71-75.
43. Akaza K., Watanabe T., Akiyama S., Kondo T. Analysis of cell surface antigens of gastric cancer and preliminary study of clinical application by using mouse monoclonal antibodies produced against NUGC3. Nippon Geka Gakkai Zasshi 1985, 86:455-463.
44. Nanba D., Higashiyama S. Dual intracellular signaling by proteolytic cleavage of membrane-anchored heparin-binding EGF-like growth factor. Cytokine Growth Factor Rev. 2004, 15:13-19.
45. Joo C.K., Kim H.S., Park J.Y., Seomun Y., Son M.J., Kim J.T. Ligand release-independent transactivation of epidermal growth factor receptor by transforming growth factor-beta involves multiple signaling pathways. Oncogene 2008, 27:614-628.